[1]魏绮琪,张 颖.miR-200c与卵巢癌关系的研究[J].医学信息,2020,33(03):53-55.[doi:10.3969/j.issn.1006-1959.2020.03.016]
　WEI Qi-qi,ZHANG Ying.Study on the Relationship Between miR-200c and Ovarian Cancer[J].Medical Information,2020,33(03):53-55.[doi:10.3969/j.issn.1006-1959.2020.03.016]
点击复制

miR-200c与卵巢癌关系的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年03期
页码:
53-55
栏目:
综述
出版日期:
2020-02-01

文章信息/Info

Title:
Study on the Relationship Between miR-200c and Ovarian Cancer
文章编号:
1006-1959（2020）03-0053-03
作者:
魏绮琪; 张 颖
（1.广东医科大学，广东 湛江 524000；2.广东医科大学附属医院妇产科，广东 湛江 524000）
Author(s):
WEI Qi-qi1; 2; ZHANG Ying1
(1.Guangdong Medical University,Zhanjiang 524000,Guangdong,China;2.Department of Obstetrics and Gynecology,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,Guangdong,China)
关键词:
卵巢癌; miRNA; miR-200c; 侵袭转移; 化疗耐药
Keywords:
Ovarian cancer; miRNA; miR-200c; Invasive metastasis; Chemoresistance
分类号:
R730
DOI:
10.3969/j.issn.1006-1959.2020.03.016
文献标志码:
A
摘要:
卵巢癌是女性常见的恶性肿瘤之一，病死率较高。MicroRNA （miRNA）是一类广泛存在于真核生物中的非编码RNA（ncRNA），其通过靶向结合蛋白编码基因的3’UTR序列，参与基因表达调控。miR-200家族包括miR-200a、miR-200b、miR-200c、miR-141和miR-429，与卵巢癌发展、转移、耐药及预后密切相关，其中研究证实miR-200c是多种肿瘤的潜在转移相关因子，在卵巢癌中的作用也受到广泛关注。本文从miRNA的形成、生物学功能、miR-200c在卵巢癌中的表达、对卵巢癌侵袭转移的影响及其对卵巢癌化疗的影响作一综述。
Abstract:
Ovarian cancer is one of the common malignant tumors in women, with a higher mortality rate. MicroRNA (miRNA) is a type of non-coding RNA (ncRNA) widely found in eukaryotes. It is involved in gene expression regulation by targeting the 3’UTR sequence of a gene encoded by a binding protein. The miR-200 family includes miR-200a, miR-200b, miR-200c, miR-141, and miR-429, which are closely related to the development, metastasis, drug resistance, and prognosis of ovarian cancer. Studies have confirmed that miR-200c is a tumor The role of potential metastasis-related factors in ovarian cancer has also received widespread attention. This article reviews the formation of miRNA, its biological functions, the expression of miR-200c in ovarian cancer, its effect on ovarian cancer invasion and metastasis, and its effect on ovarian cancer chemotherapy.

参考文献/References:

[1]Siegel RL,Miller KD,Jemal A.Cancer Statistics,2017[J].CA,2017(67):7-30. [2]Zuberi M,Mir R,Das J,et al.Expression of serum miR-200a,miR-200b and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features[J].Clin Transl Oncol,2015,17(10):840. [3]Pignata S,Pisano C,Di Maio M,et al.Medical treatment of resistant or recurrent epithelial ovarian cancer[J].Ann Oncol,2006,17(7):i49-i50. [4]Rooth C.Ovarian cancer:risk factors,treatment and management[J].British Journal of Nursing,2013,22(Sup17):S23-S30. [5]蒋少云,薛栋,邓嘉胤.小分子RNA在干细胞成骨及成软骨分化中的作用[J].口腔医学研究,2015,31(8):845-847. [6]Lee RC,Feinbaum RL,Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell,1993,75(5):843-854. [7]Gregory PA,Bracken CP,Bert AG,et al.MicroRNAs as regulators of epithelial-mesenchymal transition[J].Cell Cycle,2008,7(20):3112-3118. [8]Senfter D,Madlener S,Krupitza G,et al.The microRNA-200 family:still much to discover[J].Biomolecular Concepts,2016,7(5-6):311-319. [9]Tay Y,Zhang J,Thomson AM,et al.MicroRNAs to Nanog,Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation[J].Nature,2009,458(7237):538. [10]Wu H,Wang Q,Zhong H,et al.Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next generation sequencing[J].Oncol Rep,2019. [11]Si L,Jiang F,Li Y,et al.Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-200c is involved in the anti-migrationinvasion effects of arsenic trioxide on human breast cancer cells[J].Mol Carcinog,2015,54(9):859-869. [12]Zhu SH,He XC,Wang L.Correlation analysis of miR-200b,miR-200c,and miR-141 with liver metastases in colorectal cancer patients[J].Eur Rev Med Pharmacol Sci,2017,21(10):2357-2363. [13]Shen YA,Lin CH,Chi WH,et al.Resveratrol Impedes the Stemness,Epithelial-Mesenchymal Transition,and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation[J].Evid Based Complement Alternat Med,2013(2013):590393. [14]Cao Q,Lu K,Dai S,et al.Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer[J].Int J Clin Exp Patho,2014,7(5):2392. [15]Pendlebury A,Hannan NJ,Binder N,et al.The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer[J].Biomed Rep,2017,6(3):319-322. [16]张宝玺,刁海丹,李江宁.lncRNA MALAT1和miR-200c在卵巢癌中的表达关系及临床意义[J].河北医药,2019,41(4):489-493. [17]Meng X,Müller V,Milde-Langosch K,et al.Diagnostic and prognostic relevance of circulating exosomal miR-373,miR-200a,miR-200b and miR-200c in patients with epithelial ovarian cancer[J].Oncotarget,2016,7(13):16923. [18]施君,叶婧,周舟,等.miRNA-200c在IIIc期卵巢浆液性囊腺癌中的表达及其参与癌转移中的作用[J].现代免疫学,2016,36(1):36-41. [19]陈志铭,任爽,纪妹.miRNA-200c在上皮性卵巢患者血清中的表达及其与临床特征关系的研究[J].医药论坛杂志,2017,38(5):35-37. [20]Sulaiman SA,Ab Mutalib N,Jamal R.miR-200c Regulation of Metastases in Ovarian Cancer:Potential Role in Epithelial and Mesenchymal Transition[J].Front Pharmacol,2016(7):271. [21]吴海湉,张越,林其德,等.miR-200c过表达对OVCAR-3卵巢癌细胞生物学行为的影响[J].国际妇产科学杂志,2014,41(5):509-512. [22]Chen D,Zhang Y,Wang J,et al.MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ovarian cancer stem cells by regulating epithelial-mesenchymal transition[J].J Ovarian Res,2013,6(1):50. [23]鲁艳明,银铎,王宁,等.miRNA-200c对卵巢癌细胞侵袭能力影响观察[J].中华肿瘤防治杂志,2014,21(10):732-735. [24]Cochrane DR,Spoelstra NS,Howe EN,et al.MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents[J].Mol Cancer Ther,2009,8(5):1055-1066. [25]Sun N,Zhang Q,Xu C,et al.Molecular regulation of ovarian cancer cell invasion[J].Tumour Biol,2014,35(11):11359-11366. [26]Prislei S,Martinelli E,Mariani M,et al.MiR-200c and HuR in ovarian cancer[J].BMC Cancer,2013,13(1):72. [27]陈志铭,任爽,纪妹.miRNA-200c对卵巢癌A2780/DDP细胞顺铂耐药性的影响[J].医药论坛杂志,2017,38(7):44-46. [28]刘杰,余芙蓉,董巍檑,等.miR-200c调控人类卵巢癌对紫杉醇敏感性的影响研究[J].临床合理用药杂志,2019,12(23):136-137. [29]Gao N,Tian J,Shang Y,et al.Catalpol Suppresses Proliferation and Facilitates Apoptosis of OVCAR-3 Ovarian Cancer Cells through Upregulating MicroRNA-200 and Downregulating MMP-2 Expression[J].Int J Mol Sci,2014,15(11):19394-19405.

相似文献/References:

[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
　YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Medical Information,2018,31(03):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
　JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Medical Information,2019,32(03):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
　LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Medical Information,2019,32(03):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(03):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]赵瑶瑶,高 川,胡佳杰.循环miRNA监测肝细癌的研究[J].医学信息,2019,32(08):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
　ZHAO Yao-yao,GAO Chuan,HU Jia-jie.Research on the Study of Circulating miRNA for Monitoring Hepatocellular Carcinoma[J].Medical Information,2019,32(03):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
[6]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
　XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Medical Information,2019,32(03):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[7]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(03):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[8]胡嘉莉,华 琳.miRNA-mRNA双重表达谱在前列腺癌分子调控机制中的作用[J].医学信息,2022,35(16):18.[doi:10.3969/j.issn.1006-1959.2022.16.004]
　HU Jia-li,HUA Lin.Role of miRNA-mRNA Dual Expression Profile in Molecular Regulation of Prostate Cancer[J].Medical Information,2022,35(03):18.[doi:10.3969/j.issn.1006-1959.2022.16.004]
[9]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
　HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Medical Information,2019,32(03):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[10]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
　WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Medical Information,2019,32(03):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]

更新日期/Last Update: 2020-02-01